LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
1. Analyze breakthrough treatments in the management of advanced and metastatic hormone sensitive prostate cancer (mHSPC) and castration resistant prostate cancer (CRPC).
2. Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC.
3. Describe the indications, sequencing and combinations for treatment with approved agents in the management of mHSPC and nmCRPC.
ACKNOWLEDGEMENTS
This educational series is supported by independent educational grants from:
- Astellas
- AstraZeneca
- Bristol Myers Squibb
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Merck
- Pfizer, Inc
- Sanofi Genzyme
- UroGen Pharma, Inc.